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The aim of this paper is to explore technological roadmaps to identify key issues 
concerning the development and utilization of stem cells. From a review of the political 
decision making processes in three countries, Denmark, the Netherlands, and Germany 
we suggest that technological roadmapping in this emerging and discontinued 
technology can provide critical policy information. This type of policy intelligence can 
be used to rethink the regulatory practices away from today’s framework based 
regulation of the emerging technologies towards a regulatory policy based on how to 
develop regulatory practices based on the content and visions of the technologies in 
question. In the conclusion we discuss that the positive side effect of such a shift in the 
regulatory paradigm is that technological roadmapping can be used as a planning tool to 
deal with priorities in the health care system when the technologies are in its embryonic 
stage. 
 








Stem cell therapy is an emerging technology in its embryonic stage, and holds 
promise for diseases where cells are damaged or malfunctioning, and might be 
replaced. The ultimate potential of stem cell is to grow new cells (e.g. neurons), 
tissues and entire organs, at first outside the body but eventually in the body. Thus, 
stem cell therapy is an example of a technology with high expectations but also how 
science and technology (S&T) interplay with societal issues in increasingly complex 
ways. This make studies encompassing visions of future possible technological 
developments desirable together with tools that can facilitate and provide a more solid 
basis of regulations of the technology development. 
  
Recently, stem cells have received much attention due to the promises of the 
technology on the one hand and due to uncertainties of how to govern the 
technological development through biomedical and ethical regulations on the other. 
Future expectations and promise are crucial to providing the dynamism and 
momentum upon which the ventures in science and technology depend. However 
failure of expectations can severely damaged the reputation and credibility of 
professions, institutions and industry [1]. Technologies in their early stage like stem 
cell technologies practical utility and value has yet to be demonstrated. Therefore 
tempting for actors with invested interests like researchers and industry to exaggerate 
the expectations and down play risks and other issues that may alter or delay the 
technological development all together. Therefore, to secure value for multiple 
stakeholders stem cell research calls for adequate regulatory initiatives that can be 
standardised across EU, which in turn make a forward view of the technology path 
desirable. 
 
The technology path of stem cell technologies, however, is difficult to foresee due to 
the early stage of the technology and numerous uncertainties thanks in part to the 
bioethical controversies. Firstly, the discontinuous nature of the technology (i.e. 
derived from science based radical innovations) make a retrospective view of the past 
difficult, which otherwise could help to foresee (possible) future developments. 
Secondly, there is a lack of coordination of stem cell research activities across 
governments, non-government agencies, and the private sector in the EU as well as in 
the US. Thirdly, public hesitance due ethical issues has a significant impact on the 
future development of stem cell research. Especially research associated with the most 
promising stem cells; the totipotent fertilized egg, and the pluripotent embryonic stem 
cells. Finally, while private companies are interested and support stem cell research 
they will not decide to be involved in it before the appearance of the first stem cell 
products that meet a genuine marked need. 
 
These uncertainties make it virtually impossible to predict which type of stem cells or 
which methods for manipulating the cells, will best meet the needs of basic research 
and clinical applications. Only more research can provide these answers. Research in 
both EU and the US is strongly dependent on a definite political attitude towards the 
ethical dilemmas on performing research on embryonic stem cells. It appears clearly 
that public regulatory initiatives in the field are very diverse and incomplete, making 
the operational climate for basic research as well as innovative healthcare companies 
unsettling. However, it is important that EU regulation keeps up with future global 
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trends. Otherwise it can be expected that biotech enterprises will move their stem cell 
activities to other parts of the world where their activities can be undertaken. 
 
In this paper we will consider roadmaps as a method to provide intelligence for S&T 
policy-making considering governance of the technological path in two principal 
ways: by regulating on the technological framework of the technology or by 
regulating on the content and visions of the technologies. Regulating on the 
technological frameworks implies either that public regulation approve that the 
technologies can be used in research and development or the technology in question is 
banned by law. Regulating on the content and visions of the technologies implies that 
the public regulation allow the use in some specific areas (i.e. diseases or specific 
applications) and restrict other areas. In the case of stem cells it could for instance be 
that the Danish government solely approved the use of the surplus of eggs from in 
vitro fertilization (IVF) (embryonic stem cells) in the research and development of 
diabetes and Parkinsons’s disease since these diseases both economically and socially 
are burdensome for the individuals and the society. At the same time Denmark holds a 
strong position research position in these two areas of application and has a 
biotechnology industry that seeks to develop cures and medicines for these diseases or 
disorders. The advantage of regulating on the content instead of regulating of the 
technological frameworks is that national, regional and global issues together with 
specialized research capabilities help to make priorities in an area where the public 
expenses are almost uncontrollable. 
 
2. Methodology 
From table 1, which is taken from a recent IPTS-report [2] it appears that the 
technological roadmapping technique has undergone developments that allow it to be 
applied in an increasingly broader range of areas including technological foresight 
(TF) for public sector use. It is a series of techniques that have been developed from 
strategic models to forecast and predict how individual companies could plan their 
R&D effort and turn their development projects into feasible technologies that served 
specific market needs. In turn these road mapping techniques have been developed 
and used to focus on technological segments taking into account that new 
technologies often are a joint activity involving both private and public sector 
institutions and firms. In its latest version technological road mapping is a public 
intelligence framework that can be used to sketch the societal effects of new complex 
technologies that in order to be developed and utilized need to be discussed both in 
terms of its aims and goals, but also has be discussed in terms the society’s ethical and 
moral values. The public debate has been present for many years in areas such as 
genetic engineering, genetic modified foods, plant biotechnology and cloning. We 
believe that stem cells are just another prominent example of such a technology in the 
area of new biotechnologies tailored for health care system.   
 
In our analysis of the debate concerning stem cells we have selected three EU member 
states where we have focused attention on to the value laden discussion that have lead 
to decisions on regulative procedures of stem cell technologies together with its future 
areas of application. Through this analysis we can foresee that the scope of the stem 
cell techniques is so multifaceted that it calls for a new type of regulatory procedures 
to be implemented in order to facilitate a more precise societal discussion on this 
issue. The intention is to use the output of such an analysis to display 
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national/regional core competencies in the area of stem cells. These areas of 
specialization have to be discussed separately guided by specific technological 
roadmapping procedure in terms of its costs, benefits, ethical problems etc. The 
challenge is to develop a selective “picking the winner strategy” that allows a new 
type of regulatory system to be developed.  
 
********** 
table 1  about here 
************* 
 
In this particular article we regard roadmaps as a means of providing policy 
intelligence focusing on the interaction between actors of concern and some central 
issues in the context of a welfare economic problem where the demand for high 
quality services and the demand for up to date treatment and technologies in the 




3. To cases of political governance of the technology path 
 
What follows is a review of the discussion and policy decisions in three countries 
Netherlands, Denmark and Germany. These three EU member states have all 
experienced an intense public debate concerning the use of stem cells that took place 
at the very same time. Also the nature of the debate has been similar since the focus of 
the discussions has been on whether to allow or ban the research on embryonic stem 
cells. Despite these similarities the outcome and decision concerning research on stem 
cells have been very different in the three countries. The cases will later be used in the 
development of roadmaps for stem cell technologies and how these roadmaps 
illustrate the need for changes in the regulatory procedures. 
 
The Danish case 
 
In April 2003 the Danish minister on heath introduced a bill to legalize research on 
stem cells from fertilized eggs left over from fertilization treatments. Research on this 
type of embryonic stem cells has hitherto been illegal. 
 
The background for the bill was an inquiry debate in the parliament in January 2001 
on xenotransplantation. Here the Minister of interior and health, the Minister of 
Justice, and the Minister of Science, Technology and Innovation was asked to form a 
committee (committee of gene technology). The task of the committee was to prepare 
a report that could clarify possibilities and risks for the new biotechnologies. This 
report was finalized in October 2002 [3] and was a technical memorandum that did 
not suggest any action, but came up with a number of recommendations on problems 
that needed a political stand, and which legal complications it would have. 
  
The committee considered stem cell therapy most promising from a technical 
perspective and recommended a political and legal clarification of the area as soon as 
possible in parallel with a public debate. 
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BIOSAM, a cooperation board consisting of a number of committees and councils on 
ethic questions concerning research and applications of biotechnology [4], arranged a 
hearing, where scientists and politicians debated whether research on embryonic stem 
cells could be conducted in Denmark. The outcome of this confrontation was a 
consensus recommendation to legalize research on embryonic stem cells. 
Also The Ethical Council [5] forwarded its members opinions, which in general also 
was positive towards research on embryonic stem cells. 
 
On the basis of the report from the Committee on Gene Technology, the debate in the 
parliament, the hearing and other dialogs and debates, the government has taken a 
stand on research on embryonic stem cells. Thus it is the Danish government’s 
conception that it through an amendment to the existing legislation on in vitro 
fertilization should be legal to perform research on embryonic stem cells in 
anticipation of developing new possibilities to treat human diseases. This stand was 
joined by the parliament and became law the 27. May 2003 with out further 
modification. Thus both adult human stem cells from fetal abortions and adults and 
embryonic human stem cells are fully obtainable under the revised biomedical and 
ethical guided committee regulations in Denmark. 
 
The Dutch case 
 
The following description is based on Loes Katers work on the Regulation of stem 
cell technologies in the Netherlands [ 6]. 
 
In 1995 the Dutch Government stated that creating embryos for scientific purposes 
was not allowed. 
 
The first advice report about embryonic stem cells was published by the Health 
Council in 1997 (an advisory body of the government). The report was based on a 
brief review of the literature on research with animals and on a consultation meeting 
with four experts in the field of genetics, molecular and developmental biology. First, 
the Health Council was positive on the use of human embryos in order to establish 
embryonic stem cell lines. Second, it pleaded for extending the scope of research on 
embryos if an important public health interest was to be expected. 
 
In 1998 the Health Council came out with their final report on the regulation of IVF, 
recommending legalizing creation of embryos for scientific purposes.  
 
In 1998 the then Minister of Public Health, Welfare and Sports and the then Minister 
of Department of Justice concluded that the “ethical, legal and social analysis from 
the Health Council was not sufficient to accept that a similar change in opinion had 
taken place in society as in the Health Council”. However, the report gave occasion to 
three hearings arranged by Ministry of Public Health, Welfare and Sports. Based on 
these hearings and on an international comparison of legislation the two Ministers 
both concluded that there was no broad, sufficient social basis to create embryos for 
scientific purposes. The political solution was to place the creation of embryos for 
research under a moratorium in the Embryo Act. However within three to five years a 
decision will be taken about when to lift this moratorium. It is expected that 
developments in science and society will move towards an approval of the creation of 
embryos for scientific research. The pragmatic thinking behind this somewhat 
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enlightenment idea is the further development of scientific research. Within five years 
time the cultural and scientific climate for embryo research will probably be different 
from today’s climate. Thus the expectation is that creation of embryos for scientific 
research is not allowed at the moment but probably will be in the future. 
 
The German case[7] 
 
Germany had until Spring 2003 banned all research in embryonic stem cells. 
However, leading German researchers threatened to leave the country to carry out 
their research elsewhere. This situation let to a policy where the Bundestag decided to 
established an Ethics Commission for Stem Cell Research under the Ministry of 
Health to monitor the implementation of very strict guidelines for importation of 
existing stem cell lines. By taking this decision the German parliament has developed 
a policy that comes very close to the American public policy where the Bush 
administration in August 2001 decided that public research in stem cells where only 
allowed on nine existing stem cell lines [8].  
 
4. Review of Stem cell technologies  
 
The above described political process towards a regulation of stem cell research and 
its applications are based on a general and broad understanding of the technology. 
Since stem cell technologies are very complicated and multi faceted, the implication 
of taking decisions on the basis of a general understanding become “an either or 
decision” (go or no-go). Alternatively, as illustrated by the Dutch case it may lead to 
an empty decision awaiting the future development for research in the area. 
 
In the following we provide a technical and brief introduction to stem cell 
technologies and applications that are necessary for making roadmaps for the 
technology both in general and for more specific applications. 
 
Some of the most severe and disabling diseases and medical conditions, such as 
Parkinsons Disease, Alzheimer’s, liver damage, osteoporosis, stroke, insulin 
dependent diabetes (Type I), etc., are due to diseased or damaged cells division that 
exceeds the body’s own abilities to repair. Researchers have for years looked for ways 
to use stem cells to replace cells and tissues that are damaged or diseased. 
 
Another potential for stem cell technology is “cell factories” for local or systemic 
delivery of defined cell products such as hormones and other cell signalling 
compounds known to prevent or protect against disease and cell death. 
A better understanding of the genetic and molecular controls of these processes can 
yield information about how such diseases arise and suggest new strategies for 
therapy. A significant hurdle to this use and most uses of stem cells is to uncover the 
secrets behind the signals that turn specific genes on and off to influence the 
differentiation of the stem cell.  
 
Stem cells are cells that have the ability to differentiate into other types of cells and 
potential use for cell-based regenerative therapies. Their proliferative capacity 
combined with the ability to become specialized makes stem cells unique. 
The ultimate (totipotent) stem cell is the fertilized egg, from which derives a hierarchy 
of gradually specifying stem cells that form the tissues and organs of the foetus and 
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support growth and repair in the newborn and adult individual. These cells can give 
rise to another embryo and thus all tissue types. Once the fertilized egg has developed 
to the early blastocyst stage, pluripotent EMBRYONIC stem cells develop in the so-
called inner blastocyst cell mass. These cells have the potential to form all tissues in 
the body, but cannot develop into a new living foetus. The embryonic stem cells soon 
differentiate into lineages of multipotent stem cells, destined to form the various 
tissues and organs in the foetus. Tissue-specific stem cells are abundant in fetal tissues 
and organs, and remain present in reduced numbers in the newborn and later in most, 
if not all, tissues and organs of the adult individual. The tissue-residing “ADULT” 
stem cells are the basis for growth and repair of tissues throughout life. But tissues 
differ in this respect with good repair of skin, but poor or insufficient repair of brain 
and spinal cord or pancreatic insulin-producing cells1.  
History and development 
Embryo stem cells developed from the beginnings of IVF, when oocytes were 
matured and fertilized in vitro in the early sixties. Moving to clinical work involved 
aspirating fully mature human oocytes. These oocytes could be fertilized in vitro, and 
grew through cleavage stages to blastocysts, and then a large embryonic disc. Embryo 
transfers to the uteri of infertile patients were initially unsuccessful, but in 1978 the 
first IVF baby was born in Britain. Human blastocysts cultured in vitro had the same 
developmental possibilities as those growing in vivo, enabling work to begin on 
human stem cells for therapeutic purposes (Edwards, 2001). The isolation, culture, 




The American Association for the Advancement of Science and Institute for Civil 
Society has listed the following examples of potential stem cell applications (AAAS 
and ICS, 1999): 
 
“Type 1 Diabetes in Children. Type 1diabetes is an autoimmune disease characterized 
by destruction of insulin producing cells in the pancreas. Current efforts to treat these 
patients with human islet transplantation in an effort to restore insulin secretory 
function (obtained from human pancreas) are limited severely by the small numbers 
of donated pancreas available each year combined with the toxicity of 
immunosuppressive drug treatments required to prevent graft rejection. Pluripotent 
stem cells, instructed to differentiate into a particular pancreatic cell called a beta cell, 
could overcome the shortage of therapeutically effective material to transplant. They 
also afford the opportunity to engineer such cells to effectively resist immune attack 
as well as graft rejection. 
 
Nervous System Diseases. Many nervous system diseases result from loss of nerve 
cells. Mature nerve cells cannot divide to replace those that are lost. Thus, without a 
“new” source of functioning nerve tissue, no therapeutic possibilities exist. In 
Parkinson’s disease, nerve cells that make the chemical dopamine die. In Alzheimer’s 
disease, cells that are responsible for the production of certain neurotransmitters die. 
                                                 




In amyotrophic lateral sclerosis, the motor nerve cells that activate muscles die. In 
spinal cord injury, brain trauma, and even stroke, many different types of cells are lost 
or die. In multiple sclerosis, glia, the cells that protect nerve fibers are lost. Perhaps 
the only hope for treating such individuals comes from the potential to create new 
nerve tissue restoring function from pluripotent stem cells. Remarkably, human 
clinical experiments have demonstrated the potential effectiveness of this approach to 
treatment. Parkinson’s patients have been treated by surgical implantation of fetal 
cells into their brain with some benefit. Although not completely effective, perhaps 
owing to lack of sufficient numbers of dopamine secreting cells, similar experiments 
using appropriately differentiated stem cells should overcome those obstacles. More 
complex experiments have already been successfully conducted in rodent models of 
Parkinson’s. Similar approaches could be developed to replace the dead or 
dysfunctional cells in cortical and hippocampal brain regions that are affected in 
patients with Alzheimer’s. 
 
Primary Immunodeficiency Diseases. Pluripotent stem cells could be used in 
treatment of virtually all primary immunodeficiency diseases. Presently, there are 
more than 70 different forms of congenital and inherited deficiencies of the immune 
system that have been recognized. These are among the most complicated diseases to 
treat with the worst prognoses. Included here are diseases such as severe combined 
immunodeficiency disease (the “bubble boy” disease), Wiskott-Aldrich Syndrome, 
and the autoimmune disease lupus. The immune deficiencies suffered as a result of 
acquired immune deficiency syndrome (AIDS) following infection with the human 
immunodeficiency virus are also relevant here. These diseases are characterized by an 
unusual susceptibility to infection and often associated with anaemia, arthritis, 
diarrhea, and selected malignancies. However, the transplantation of stem cells 
reconstituted with the normal gene could result in restoration of immune function and 
effective normalization of life span and quality of life for these people. 
 
Diseases of Bone and Cartilage. Stem cells, once appropriately differentiated, could 
correct many diseases and degenerative conditions in which bone or cartilage cells are 
deficient in numbers or defective in function. This holds promise for treatment of 
genetic disorders such as osteogenesis imperfecta and chondrodysplasias. Similarly, 
cells could be cultivated and introduced into damaged areas of joint cartilage in cases 
of osteoarthritis or into large gaps in bone from fractures or surgery. 
 
Cancer. At the present time, bone marrow stem cells, representing a more committed 
stem cell, are used to rescue patients following high dose chemotherapy. 
Unfortunately, these recovered cells are limited in their capacity to restore immune 
function completely in this setting. It is hoped that injections of properly 
differentiated stem cells would return the complete repertoire of immune response to 
patients undergoing bone marrow transplantation. Complete and functional restoration 
will be required if, for example, immune/vaccine anticancer therapy is to work. More 
importantly, success would permit use of very toxic (and effective) chemotherapeutic 
regimens that could not currently be utilized for lack of an ability to restore marrow 
and immune function.” 
 
Additional therapeutic potential includes stem cell-derived “cell factories” for local or 
systemic delivery of defined cell products such as hormones, growth factors and other 
cell signalling compounds known to prevent or protect against disease and cell death. 
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Non therapeutical applications of stem cells is testing of new drugs. For example, new 
medications could be tested for safety on differentiated cells generated from human 
pluripotent cell lines. Other kinds of cell lines are already used in this way. Cancer 
cell lines, for example, are used to screen potential anti-tumor drugs. But, the 
availability of pluripotent stem cells would allow drug testing in a wider range of cell 
types. However, to screen drugs effectively, the conditions must be identical when 
comparing different drugs. Therefore, scientists will have to have knowledge to 
control the signals responsible for the differentiation of stem cells into the specific 
cell type on which drugs will be tested. 
 
An in-depth discussion of the future for stem cell research can be found in a special 
issue of Nature vol. 414, 2001. 
 
5. Towards a roadmap for Stem cell therapies 
 
The rational behind technology roadmapping for the provision of intelligence for S&T 
policy-making approach is described in the previously mentioned IPTS-report. It 
consists of relating major political or socio-economic issues, seen as potential outputs 
of R&D developments, back to the present S&T policies through various 
technological paths. Thus issues becomes the “nodes” of future steps in S&T 
development that have to be related to the present S&T policies through various 
technological paths. 
In figure 1 we have drawn a hypothetical2 roadmap where Science & Technology, and 
ethics are chosen as examples of issues that both have a mutual interaction and a 
major potential influence on the technological path. 
Science and technology 
 
A key to develop new treatments of diseases where cells are damaged or 
malfunctioning is a better understanding of the genetic and molecular controls of cell 
division and differentiation processes. Limited types of stem cell therapies are already 
in use. The most well-known therapy is the stem cell transplant (a form of a bone 
marrow transplant) for cancer patients. For Parkinson’s disease therapies are expected 
in the near future (5 years or so) since its underlying brain chemistry is well defined. 
Therapies for multifactorial diseases such as Alzheimer’s, which affects the entire 
brain, are not to be expected in the nearest 10 years. 
 
Both nationally as well as internationally, attention is focused on embryonic stem 
cells because it is assumed they have the greatest potential. However, there is 
increasing evidence that adult stem cells e.g. from cord blood and fully developed 
tissue, might exhibit a potential similar to that of embryonic stem cells. Adult stem 
cells may even be better at making some tissues, but this work is at an even earlier 
stage. Therefore therapies based on adult stem cells will probably be applied a few 
years later than embryonic stem cells. 
                                                 
2 The construction of a profound roadmap require that experts and stakeholders from various 
disciplines and interests discuss which issues should be considered in the roadmap and their potential 
implications for the technological path. Here we have only consulted the literature and interviewed a 




Ethical hesitance is largely concentrated around considerations on the use of 
embryonic stem cells. The use of spare embryos from IVF as a source of 'raw 
material' (in this case, stem cells) is controversial. By some, the concept is fully 
rejected. Others, on the contrary, feel that the very fact that these embryos exist and 
are stored independently of any parental plan, and given the high hopes they raise for 
treating certain diseases, makes their use ethically acceptable (see e.g. 
http://www.ccne-ethique.org/english/start.htm, visited 25.10.2003). It should be 
mentioned that the fact that adult stem cells derive from abortions, also might raise 
ethical considerations.  
 
The attitude towards research in embryonic stem cells represents an ethical value 
conflict that places society against a choice between to possibilities both having 
inevitable moral consequences and costs.  Such perspectives demand an ongoing, 
open and broad debate and a definition of a political position ( Danish Ministry of 
Science, 2002). In agreement with this OECD has declared that a social consensus is 
needed before opposition to such research overwhelms the common good it provides. 
Therefore, dissemination and translation of research findings is essential if the public 
is to understand, support and ultimately benefit from the research effort [9]. 
 
***************** 




Implication for regulating on the framework 
 
“Restrictions on the number of cell lines coupled with insecurity over continued 
funding has made researchers shy away from this field […] It’s clear the presidents 
[Bush, red.] policy has a chilling effect that goes well beond the literalrestriction of 
the policy” (Sean Tipton, vice president of communication for the Coalition for the 
Advancement of Medical Research) [10]. 
 
The three described cases demonstrate three different routes or technology path for 
stem cell therapy when ethical issues are an important issue for policy and legal 
clarification. If we return to the roadmap the consequences of the political and legal 
clarification for stem cell research and potential therapies can be outlined. 
 
The legal clarification allows Danish researchers to proceed with the promising 
embryonic stem cells. Denmark may even be able to attract top researchers from 
countries that more restrictive towards research on stem cells thereby strengthening 
innovation and attract venture capital, at the expense of for example The Netherlands. 
However it is important to continue the debate on ethical issues, both to secure 
transparency for the public and to prepare for commercial applications of stem cell 
therapy, where new issues surely will appear high on the agenda and influence the 
direction and rate of the technological path. 
 
In the Dutch case, on contrary, researchers are restricted to work within the guidelines 
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of the Embryo Act and the moratorium. It is up to a political appointed group of 
experts, organized in the Central Committee for Medical Research Involving Human 
Subjects (known by its Dutch initials as: CCMO) to decide in these morally complex 
issues. This makes long term planning of research difficult and probably do not 
promote financial support from non-governmental resources. Both top researchers and 
industry will be tempted to move to countries that are less restrictive towards research 
on stem cells. On the other hand resources may be allocated towards the less ethically 
problematic multi-potent adult stem cells allowing improved progress in this research 
field. However, the “what and see” attitude behind the political solution of the Dutch 
government will increase uncertainty and keep knowledge and venture capital away. 
 
The German case is an example where the political process has lead to a strict 
regulation only allowing research on embryonic stem cells to be undertaken under 
guidelines that seriously limit the scientific progress. In reality this leads to a situation 
similar to that in the US, which has lead to a de facto moratorium of the research on 
embryonic stem cells as reflected in the quotation from Sean Tipton that initiated this 
section. 
 
It appears clearly that public regulatory initiatives in the field are very diverse and 
incomplete, making the operational climate for innovative healthcare companies 
unsettling. It is important that EU regulation keeps up with future global trends. 
Otherwise it can be expected that biotech enterprises will move to other parts of the 
world where their activities can be undertaken. This is due to the fact that the 
biotechnological field of enterprises consist of a number of overlapping and flexible 
environments built on very specific knowledge networks in the form of transnational 
strategic alliances, research collaboration etc. [11]. 
 
The above outlined scenarios are essential an outcome of regulating by the 
technological frameworks. This leads to a situation where the less restrictive countries 
can precede research and development on the expense of the more hesitant countries. 
In the following we suggest an alternative mode of regulation that take societal 
concerns seriously and e.g. allow ethical issues to become an integrated part of 
conducting research. This is expressed in the following quotation from Micheal 
Kalichman, Director of the research Ethics Program at the University of California:  
“Both the conduct of science and ethics are best defined not by a particulary endpoint 
but by a process. The good news is that considerations of long-term interests can often 
yield options that are at the same time ethically defensible and practically beneficial” 
[12]. 
 
An alternative regulatory procedure 
 
In figure 2 we have drawn a hypothetical roadmap for the technological development 
of a specific application of stem cell therapy namely Parkinson’s disease. The 
objective is to illustrate how the roadmap also can help to get an overview of the 
consequences that a regulation on the content and visions might have for the 
technological path. 
 
Science and technology 
Patients with Parkinson's disease have lost large numbers of a particular key type of 
brain cell that produces a chemical needed for the body to control muscular 
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movements. Research at Lund University in Sweden using adult stem cells have 
already shown that it is possible to improve symptoms by partially replacing the cells 
lost to the disease. It is expected that research on embryonic stem cells will show even 
more promising results. The problem is that scientists do not yet fully understand how 
to use chemicals to mature the stem cells and generate large numbers of dopamine-
producing neurons, which are the cells need. Ultimately, different cell types might 




The ethical concerns for stem cell therapy applied to a specific application such as 
Parkinson’s are of cause substantial equivalent to those described already. However, 
since the application is delimited to a specific disease the discussion can be focused 
on concrete issues allowing it become an integrated part of the research process. 
 
*************** 
Figure 2 about here 
*************** 
 
Implications for the technology path 
 
The roadmap on stem cell technologies applied towards therapies for Parkinson’s 
disease (Fig. 1) come out much simpler than the road map for stem cell technologies 
in general (Fig. 2). Since the application is delimited to therapies of a specific disease 
interactions are less complicated and the discussion can therefore easier be focused on 
the key issues. We expect that this will be a good basis for the establishment of a 
genuine dialogue between specific experts and stakeholders that can deliver 
information to the politicians concerning how to perform a regulatory policy for the 
technology in question. The idea is to build a system where roadmapping is an 
integrated part of S&T policy and the conduct of research it self. Thus, roadmapping 
issues should be the basis for dialogue and discussion between authorities, scientists 
and interested and affected parties. Lessons learned from discussing the ethical 
dimension of research of a specific application may improve future dialogue process 
considering the application of stem cell therapy for specific diseases and in general. 
We know it is difficult to establish a forum for dialogues of this kind and we see at 
least three problems that need consideration before such forum can be implemented. 
One problem is to find criteria’s for selecting forum members such that all parties are 
treated in a democratically acceptable way. A second problem is that such a forum 
will not necessarily reach consensus. A third problem is that it has to be decided how 




We believe that the regulatory system has to be changed from being a rigid approval 
system based on technological regimes to a more elaborated system where means and 
ends are discussed on the basis of the prospects of the health care technologies. Also 
the old system will come under pressure due to the broader scope in selection of 
stakeholders and that these stakeholder’s values and beliefs will force a system shift 
so that science and technology will not be judged, reviewed and evaluated by scientist 
and industrialists. We therefore suggest a shift in paradigm that can be accordingly to 
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the roadmap system on how to make TFs that radically removes the emphasis on 
scientific representation to a dialogue based system that takes national, regional and 
even global interests into account when new technologies are approved. Moreover, 
foresee that the escalating expenditures for the health care system will force the old 
regulatory system to collapse. As suggested from our roadmap of stem cell 
technologies applied towards therapies of Parkinson‘s disease it appears that 
technological roadmaps can be used as a policy information tool to make priorities 
between not only specific technological paths, but also support decision making 
considering future developments of therapies and medicines and services for the 
health care sector. 
 
Table 1:  Categories of Technology roadmapping (From IPTS-Report 73, 20032) 
  Corporate TRM Industry TRM Goal-Oriented TRM Policy S&TRM 
Diffusion mid-1980s early 1990s mid-1990s Late 1990s 
Scope One product or a 
family of products 
A technological sector (mono-
disciplinary) 
Key enabling technologies 
for a single goal (pluri- 
disciplinary, business). Early 
appearance in the innovation 
process 
Wide S&T areas or 
whole S&T landscape 
seen from an "issue-
driven" approach and 





A single company Consortium of companies, 
national industry up to a whole 
international industry, public 
agencies, private consulting 
company 
Public agencies often acting 
as facilitator or as developer 
in a consortium of 
companies 
Think-tanks and public 
agencies 
Utilization Within the company Companies of this consortium, 
whole national or international 
industry, other stakeholders 
Various companies from 
various sectors sharing an 
interest in the same final 
goal, other stakeholders 
Policy-makers and other 
stakeholders or 
companies 
Objectives Optimizing R&D 
decisions, strategic 
planning for 
development of new 
products 
Becoming more competitive 
by sharing R&D investments 
and results in the pre-
competitive domain 
Creating common ground, 
shared identifications and 
visions for people from 
completely different 
backgrounds 
Providing the intelligence 
needed for optimizing 
public R&D investments 
and ensuring their 
relevance to society 




Workshops with industrial and 
academic experts 
Brainstorming and 
converging workshops with 
various experts and 
stakeholders 
Workshops with various 
experts and stakeholders, 
large scale semi-public or 
public conferences 





normative: "what are 
we going to do?" 
Technology-driven 
Forecasting and normative: 
"what will happen?" and "what 
we should do?" 
Problem-driven Prospective: 
"what might happen?" 





policies contribute to 
shapethe future, "the 
future depends on us", 
multiple possible futures 
Time Horizon Short term, typically  
5 years 
Medium term, typically 5 to 10 
years 
Usually longer term, up to 
20 years, may be as short as 
5 years depending on the 
industry, on the 
planning/vision, 
forecasting/foresight trade





concerns and demands )
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Figure 1: Roadmap for the application of stem cell technologies. Thin arrows indicate 
where specific issues may influence the technology path. 
 
Figure 2 Roadmap on stem cell technologies applied towards therapies for 
Parkinson’s disease 
                                                 
8 References 
 
 1 Brown N, Michael M. (2003) ‘A sociology of expectations: Retrospecting 
prospects and prospecting retrospects’, Technology Analysis and Strategic 
Management,  Vol. 15 No. 1, pp. 3-18. 
2  Da Costa, O., Boden, M., Punie, Y. and Zappacosta, M. (2003) ‘Science and 
Technology Roadmapping: from Industry to Public Policy’, IPTS report Vol. 73, 
pp.  27-32. 
3  Videnskabsministeriet (Ministry of Science and Technology) (2002):  ’Fremtidens 
bioteknologier – muligheder og risici’, Copenhagen, Denmark, 
http://www.vtu.dk/fsk/publ/2002/genteknologi/genteknologi.pdf 
4  BIOSAM: http://www.tekno.dk/biosam/ 





Cell-based repair in vivo (ES?) Clinical trails on humans???
Continued debate on the ethical dimension between stakeholders and when specific issues need attended to





Clinical test on humans using ES
Pre-clinical applications on 
embryonic stem cells (ES)
ES therapy applied to 
single factorial disease
Ethics
ES therapy applied to 
multiple factorial disease
Clinical test on humans using AS
Pre-clinical applications on 
adult stem cells (AS)
AS therapy applied to 
single factorial disease
Tissue produced ?
Debate on specific 
applicationsc
Value debate on ES 
±
±
Value debate on AS Debate on commercialisation of stem cell therapy 
Issues
 16
                                                                                                                                            
6  Kater, L. (2003) ‘Regulating stem cell technology in the Netherlands’, Biotech 
Society Conference, 29-30 September 2003, Espoo, Finland. 
7  www.germany-info.org/relaunch/business/new/bus_stemcell2.htm 
8  New Law Strictly Limits Importation of Human Embryonic Stem Cells. 
http://www.germany-info.org/relaunch/business/new/bus_stemcell2.htm 
9  OECD (2002) ‘Healthy Ageing and Biotechnology. Policy implications of new 
research’, p. 133. http://www.oecd.org  
10  Agres, T. (2003) ‘All that stemm cell money and nobody to spend it’, The 
Scientist Vol. 17, No. 20, P. 43.  
11  Norus, Jesper (2002): Biotechnology Organizations in Action – Turning 
Knowledge into Business. Elsevier, Amsterdam. 
12  Kalichman, M. 2003. Ethics and the Scientist. The Scientist Vol. 17, No. 20, P. 43. 
13  Jensen, K.K., Rasmussen, B., Borch, K., Kappel, K. (2001). ‘How should ethics 
be integrated in the approval process of genetically modified plants?’ 
EurSafe2001 - 3rd Congress of the European Society on Agricultural and Food 
Ethics, 3-5 Oct 2001, pp. 251-254. 
